IMR Press / RCM / Volume 3 / Issue S1 / pii/1561516726459-1179313629

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Practical Issues of Platelet Glycoprotein IIb/IIIa Receptor Inhibition: Saving Lives and Saving Money
Show Less
1 Genesis Heart Institute, Davenport, IA
Rev. Cardiovasc. Med. 2002, 3(S1), 28–34;
Published: 20 January 2002
Abstract
Abciximab is a monoclonal, human chimeric antibody with unique pharmacodynamics, pharmacokinetics, and receptor-specificity that distinguishes it from the small-molecule platelet glycoprotein IIb/IIIa receptor inhibitors. Abciximab has consistent, well-defined dosing and robust clinical results. Pooled data across abciximab trials comprising 9290 patients at maximum duration of follow-up demonstrates a 19% reduction in the relative risk of mortality (P = .003). There is a misperception of the cost of abciximab that focuses solely on the acquisition price of the drug. Cost-effectiveness analysis models compare the incremental improvement in clinical outcomes related to the increase in cost. Abciximab is extremely cost-effective in cost per life-year saved and is very attractive economically compared to alternative spending of health care dollars.
Keywords
Glycoprotein IIb/IIIa antagonists
Percutaneous coronary intervention
Antiplatelet
Abciximab
Cost-effectiveness analysis
Stents
Integrin
Share
Back to top